Isolation of Novel Fully Human Single-Domain Antibodies Targeting GUCY2C from a Heavy-Chain-Only Transgenic Mouse Platform.

Authors

Pingxia Zhu, Lei He, Xiaoming Du, Pengsha Pang, Zhihua Ji, Yanyu Yang, Fengqi Cao, Quanjun Wang

Published in

Technology in cancer research & treatment. Volume 25. Pages 15330338261473054. Epub Aug 11, 2026.

Abstract

IntroductionTraditional natural single-domain antibodies(sdAbs) are primarily derived from camelids and sharks. However, the large size and slow reproduction of these species limit their widespread application in antibody development. In this study, we employed a fully human heavy-chain-only antibody mouse ( huNano mouse ) platform and a rapid, efficient preparation process to successfully develop fully human heavy-chain-only antibodies(HcAbs) targeting the tumor antigen guanylyl cyclase C (GC-C). These sdAbs provide high-quality candidate molecules for subsequent GC-C-based CAR-T therapy and bispecific antibody drug development.MethodsFully huNano mice were immunized with GC-C recombinant protein. SdAb sequences specifically binding to GC-C were selected via phage display technology and subsequently cloned into mammalian expression vectors for expression and purification. The binding activity, affinity, thermal stability, and monomeric dispersion of the antibodies were systematically evaluated using various methods, including ELISA, flow cytometry (FACS), biolayer interferometry (BLI), and size-exclusion chromatography (SEC-HPLC).ResultsMultiple sdAbs with specific recognition of GC-C were successfully obtained and exhibited strong binding affinities. After one-step purification, the monomeric purity of most antibodies exceeded 95%, with aggregate content below 5%. The nanobodies exhibited good thermal stability, with melting temperature (Tm) and aggregation onset temperature (Tagg) both falling within the range of 60-68 °C, demonstrating excellent drug development potential.ConclusionThese results validate the capability of the huNano mouse platform to efficiently produce high-quality, fully human sdAbs.

PMID:
42579767
Bibliographic data and abstract were imported from PubMed on 12 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.